Sept. 30, 2025 — Biograph and Caristo Diagnostics have announced a partnership for Biograph to become the first U.S. clinic to study a novel AI-based preventive cardiac marker in asymptomatic patients, by detecting coronary artery inflammation from cardiac CT scans. Study participants will receive access to Caristo’s proprietary CaRi-Heart and CaRi-Plaque technologies to evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease in asymptomatic patients. Why Inflammation Detection Matters“Early detection of inflammation is crucial, as it often precedes plaque buildup and provides a critical window for preventing disease,” said Dr. Michael Doney, Executive Medical Director of Biograph. Study Design and Participant ExperienceIn the initial phase the study will enroll 100 of Biograph’s Black Tier members beginning in October. For more details on the partnership or to request enrollment in the study, visit www.biograph.com.